First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige) versus placebo and celecoxib in patients with knee osteoarthritis. This seven day, double-blind, placebo an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2006-01, Vol.8 (2), p.R35-R35, Article R35
Hauptverfasser:	Wittenberg, Ralf H, Schell, Ernest, Krehan, Gerhard, Maeumbaed, Roland, Runge, Hans, Schlüter, Peter, Fashola, Taiwo O A, Thurston, Helen J, Burger, Klaus J, Trechsel, Ulrich
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Analgesics - administration & dosage Analgesics - adverse effects Analgesics - therapeutic use Celecoxib Cyclooxygenase 2 Inhibitors - administration & dosage Cyclooxygenase 2 Inhibitors - adverse effects Cyclooxygenase 2 Inhibitors - therapeutic use Diclofenac - analogs & derivatives Double-Blind Method Drug Administration Schedule Female Humans Male Middle Aged Organic Chemicals - administration & dosage Organic Chemicals - adverse effects Organic Chemicals - therapeutic use Osteoarthritis, Knee - drug therapy Osteoarthritis, Knee - physiopathology Pain Measurement Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - therapeutic use Sulfonamides - administration & dosage Sulfonamides - adverse effects Sulfonamides - therapeutic use Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!